Products

LiverMultiScan
Perspectum
Gastroenterology AI
LiverMultiScan by Perspectum is an FDA-cleared, non-invasive MRI-based AI tool that quantifies liver fat, iron, inflammation, and fibrosis to aid in the diagnosis and management of chronic liver diseases.
Hepatica v1
Perspectum
Oncology AI
Hepatica v1 by Perspectum is an AI-driven clinical and surgical decision support tool that provides quantitative measurements and visualizations of liver health from MRI data, primarily for pre-surgical planning in liver cancer.
LiverMultiScan v5
Perspectum
Gastroenterology AI
LiverMultiScan v5 is an AI-powered, non-invasive MRI-based software that quantifies liver fat, iron, and fibroinflammation (cT1) to aid in the diagnosis and monitoring of chronic liver diseases.

See all 3 products →

About Perspectum

Perspectum is a precision health company that leverages artificial intelligence (AI) and advanced medical imaging, primarily multiparametric MRI, to provide non-invasive diagnostic and monitoring solutions for a range of chronic systemic diseases. Their technology aims to offer quantitative assessments of health, moving beyond traditional qualitative imaging to deliver integrated data intelligence and actionable biomarkers. This approach supports clinicians in making more informed decisions, personalizing patient care, and ultimately improving outcomes.

The company’s flagship product, LiverMultiScan, utilizes existing MRI hardware to non-invasively measure liver fat, iron, fibrosis, and inflammation, significantly reducing the need for invasive liver biopsies in conditions like non-alcoholic steatohepatitis (NASH), viral hepatitis, and liver cancer. Perspectum also offers CoverScan for multi-organ assessment, addressing conditions such as long COVID and diabetes, and MRCP+ for quantitative assessment of biliary anatomy. Their solutions are delivered via a secure, cloud-based software-as-a-service (SaaS) platform, enabling standardized data processing and patient-friendly reports for physicians globally.

Perspectum is committed to continuous clinical development and research, collaborating with world-renowned experts to expand its product pipeline into other multi-organ inflammatory conditions, oncology, and future areas like women’s health. By providing safe, fast, and comprehensive diagnostics, Perspectum seeks to empower both patients and healthcare providers with accurate, data-driven insights for early detection, diagnosis, and targeted treatment.

Focus Areas

Metabolic diseases Liver conditions (NAFLD NASH PSC AIH) Diabetes Cancer Multi-organ health Long COVID Quantitative MRI AI-driven diagnostics Contract Research Organization (CRO) solutions

Business Intelligence

Key InvestorsOppenheimer & Co. Inc., Blue Venture Fund, HealthQuest Capital, Oxford Science Innovation, Puhua Capital, University of Oxford, British Patient Capital, Grow London, Minogue Consulting
PartnershipsNuance Communications (Microsoft company), Avant Santé, InHealth, Marubeni/Clairvo, ProPath, SC Liver Research Consortium (SCLRC), Datavant, London Institute for Healthcare Engineering (LIHE)
TechnologyAI-driven quantitative multiparametric MRI (mpMRI), Cloud-based Software-as-a-Service (SaaS) platform (AWS), Proprietary biomarkers (e.g., cT1, PDFF)
FDA Clearances3 cleared products (estimated)

What Physicians Need to Know

Metabolic Diseases & Liver Conditions
Perspectum specializes in the non-invasive assessment and management of metabolic diseases and various liver conditions, including NAFLD, NASH, PSC, and AIH. Their flagship product, LiverMultiScan, provides quantitative metrics for liver fat, inflammation, and fibrosis, aiming to replace invasive liver biopsies for diagnosis and monitoring of disease progression and treatment response.
Diabetes
The company extends its multi-organ scanning capabilities to diabetes, with studies like 'Modify' focusing on understanding disease impact and progression. They offer cardiometabolic solutions within their CRO services to support clinical trials related to metabolic diseases.
Cancer
Perspectum provides oncology solutions that integrate non-invasive multi-organ and tumor characterization software, digital pathology, and endoscopy for deeper analysis of patients and their cancer. Their Hepatica tool supports surgical decision-making in liver cancer by identifying patients at risk of poor post-operative outcomes.
Multi-organ Health & Long COVID
CoverScan is a key offering for assessing multi-organ health, quantifying characteristics of six different organs (heart, lungs, kidneys, liver, pancreas, and spleen) using a single, non-contrast MRI scan. This technology has been instrumental in identifying physiological bases for Long COVID and detecting organ impairment in affected individuals.
Quantitative MRI & AI-driven Diagnostics
Perspectum's core technology involves proprietary multi-parametric MRI (mpMRI) and AI-driven diagnostics. They extract quantitative biomarkers from imaging, such as corrected T1 (cT1) and proton density fat fraction (PDFF), and use AI for tasks like delineating liver volume and segments, all delivered via a cloud-based analytics and reporting portal.
Contract Research Organization (CRO) Solutions
As a CRO, Perspectum offers Pharma Solutions providing proprietary biomarkers for identifying and monitoring disease in clinical trials. These are delivered as a turn-key medical imaging solution via a secure, cloud-based SaaS platform, covering areas like body composition, cardiometabolic, MASLD/MASH & cirrhosis, autoimmune disease, gastrointestinal disease, and oncology.
Physician Tip

Perspectum stands out for physicians by offering advanced, non-invasive, and safe diagnostic solutions that can significantly improve clinical decision-making and personalize patient care. Their quantitative MRI and AI-driven tools provide comprehensive, easy-to-interpret reports that assess entire organs, a critical advantage over partial assessments like liver biopsies. This enables earlier detection, more accurate diagnosis, and targeted treatment of chronic systemic diseases, including liver conditions, diabetes, cancer, and multi-organ impairment in Long COVID. The ability to monitor disease progression and treatment response with high precision, coupled with the potential for cost savings by reducing invasive procedures and associated complications, makes Perspectum's offerings highly valuable for enhancing patient outcomes and streamlining clinical workflows.

Perspectum's solutions are delivered as cloud-based Software as a Service (SaaS), designed for seamless integration into existing clinical workflows, including PACS-integrated services. They have also established collaborations, such as with Nuance, to scale access to their AI-enabled integrated digital care platforms across a broad network of healthcare facilities.

Products by Perspectum

3 products in the directory

LiverMultiScan
Perspectum
Gastroenterology AI
LiverMultiScan by Perspectum is an FDA-cleared, non-invasive MRI-based AI tool that quantifies liver fat, iron, inflammation, and fibrosis to aid in the diagnosis and management of chronic liver diseases.
Hepatica v1
Perspectum
Oncology AI
Hepatica v1 by Perspectum is an AI-driven clinical and surgical decision support tool that provides quantitative measurements and visualizations of liver health from MRI data, primarily for pre-surgical planning in liver cancer.
LiverMultiScan v5
Perspectum
Gastroenterology AI
LiverMultiScan v5 is an AI-powered, non-invasive MRI-based software that quantifies liver fat, iron, and fibroinflammation (cT1) to aid in the diagnosis and monitoring of chronic liver diseases.

What the Web Says

Perspectum is a healthcare technology company that develops advanced imaging solutions for diagnosing and managing chronic diseases, particularly liver conditions. Their products, like LiverMultiScan and CoverScan, utilize AI-enhanced MRI to provide non-invasive, quantitative assessments. While their products are generally viewed positively for their innovative approach to diagnostics and potential to reduce invasive procedures, employee reviews indicate some concerns regarding management and career advancement.

Overall: Mixed

Strengths

  • Innovative non-invasive diagnostic tools for liver and multi-organ assessment.
  • Potential to replace invasive procedures like liver biopsies, improving patient safety and experience.
  • Products like LiverMultiScan help patients better understand their conditions and adhere to treatment.
  • Cost-effectiveness of their software, demonstrating significant savings for healthcare systems.
  • Focus on integrated data intelligence and a patient-first approach.
  • Good company perks like gym discounts and private health insurance.

Limitations

  • Inexperienced management that may not follow regulations.
  • Lack of feedback from management, often only delivered to assign blame.
  • Non-existent promotion process.
  • Some senior management members are unwilling to provide guidance or tasks to interns.
  • Work-life balance, compensation & benefits, job security & advancement, management, and culture categories received 0.0 ratings on Indeed based on a limited number of reviews.
  • Limited number of employee reviews available, making it difficult to form a comprehensive opinion on employer satisfaction.

Based on reviews from: Indeed.com, G2.com, AuntMinnie.com, Perspectum.com, MTEC.org, PharmaTimes.com, Reddit.com

Last updated: 2026-07-18

Videos

News, demos, and interviews about Perspectum.

Loading videos...

Videos load interactively. If none appear, search YouTube for Perspectum →

View all on YouTube

Press & Coverage

Perspectum
Sir Mike Brady Elected as an International Member of the National Academy of Engineering
Sir Michael Brady, co-founder of Perspectum, has been elected to the National Academy of Engineering (NAE), one of the highest professional distinctions for engineers.
2026-02
Perspectum
Perspectum Announces Executive Leadership Changes
Dr. Rajarshi Banerjee is no longer with Perspectum, and Dr. Rexford Newbould, the company's Chief Operating Officer, has been appointed as Interim Chief Executive.
2026-01
Perspectum
Perspectum and Avant Santu00e9 announce strategic partnership to strengthen quantitative imaging for metabolic and liver research in Mexico and Latin America
Perspectum has partnered with Avant Santu00e9, a contract research organization, to enhance quantitative imaging for metabolic and liver research in Mexico and Latin America.
2025-12
Business Wire
Perspectum and InHealth Announce National Diagnostics Partnership to Boost Oxford CDC Capacity and Widen Access to Advanced MRI Across the UK
Perspectum and InHealth have formed a national diagnostics partnership to expand access to advanced MRI and increase capacity at the Oxford Community Diagnostic Centre in the UK.
2025-12
Perspectum
New analysis shows corrected T1 (cT1) is the most appropriate diagnosis and monitoring tool for widespread adoption of resmetirom treatment in the United States
Economic modeling suggests that Perspectum's proprietary biomarker cT1 is the most suitable diagnostic and monitoring tool for the widespread use of resmetirom in the US.
2025-09
Perspectum
Major Study Shows Liver Health Measured with cT1 Predicts Clinical Outcomes
A study published in Nature Medicine demonstrated that Perspectum's iron corrected T1 (cT1) predicts liver-related and cardiac outcomes, highlighting liver disease as a modifiable cardiac risk factor.
2025-05
Perspectum
Perspectum Awarded New FDA Grant to Evaluate Biomarker for Rare Disease Drug Development
Perspectum has received a new FDA grant to evaluate a biomarker for the development of drugs for rare diseases.
2024-11
BioSpace
New Published Data Show Reproducibility and Utility of Perspectum's MRI in Patients With Metabolic Liver Disease
Two new research studies affirm the utility of quantitative MRI imaging, including Perspectum's technology, as a noninvasive alternative to liver biopsy for metabolic dysfunction-associated steatohepatitis (MASH) in clinical trials and patient care.
2024-09

Frequently Asked Questions

Perspectum offers LiverMultiScanu00ae, an FDA-cleared MRI-based diagnostic that quantifies liver fat, iron, and fibroinflammatory activity for conditions like MASLD/MASH, autoimmune hepatitis, and viral hepatitis. They also provide MRCP+ for quantitative assessment of the biliary system, which can differentiate between conditions like AIH and PSC.
Perspectum's CoverScanu00ae MD is a non-invasive, multi-organ MRI assessment platform that quantifies characteristics of six different organs (heart, liver, lungs, kidneys, pancreas, spleen) in a single scan. This technology is used to assess multi-organ impairment in patients with Long COVID and metabolic diseases like diabetes.
Perspectum leverages advanced quantitative multiparametric MRI and AI-driven diagnostics to extract biomarkers from imaging, providing comprehensive insights beyond conventional methods. Their AI systems enhance disease detection, improve precision, and can potentially monitor disease progression in conditions affecting the liver and other organs.
Yes, Perspectum provides oncology solutions that integrate non-invasive, multi-organ, and tumor characterization software with digital pathology and endoscopy for rapid, deeper analysis of cancer patients. Their advanced 3D medical imaging software aids in revolutionizing oncology trials by improving standardization, reproducibility, and quantitative organ health metrics.
As a CRO solution provider, Perspectum offers proprietary biomarkers for identifying and monitoring disease in clinical trials, delivered as a secure, cloud-based software-as-a-service. They support drug development across various areas including cardiometabolic, MASLD/MASH, autoimmune, gastrointestinal diseases, and oncology, utilizing quantitative MRI and DXA.
Perspectum's LiverMultiScanu00ae is an FDA-cleared software medical device, and CoverScanu00ae MD has received MHRA clearance in the UK and FDA 510(k) clearance in the US. The company actively engages in regulatory processes for biomarker qualification, demonstrating a commitment to compliance and validated diagnostic tools.
Perspectum collaborates with world-leading experts and has established strategic partnerships, such as with Nuance (a Microsoft company) to scale access to their AI-enabled platforms across US healthcare facilities. They also partner with organizations like Avant Santu00e9 to strengthen quantitative imaging research in regions like Mexico and Latin America.

Related Companies

CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]

Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]

OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]

Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]

MedTalk AI is an Australian-based healthcare AI company focused on streamlining clinical documentation for physicians and other healthcare professionals. The company’s flagship product is an ambient AI medical scribe that listens to real clinical conversations and converts them into structured, accurate notes in real-time. This technology aims to free clinicians from the burden of manual […]

allergoSMART is a healthcare AI company that offers the world’s first AI-based complete solution for personalized mite allergen avoidance. The company’s system, allergoSMART, provides a unique AI digital solution for individuals with dust mite allergies, combining targeted prevention and treatment through comprehensive home environment optimization. [3] It integrates symptom tracking, telemedicine, and air purification into […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.